Katarzyna Tomela

Mrs. Katarzyna Tomela

Department of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BDBernadeta Drymel
Bernadeta Drymel
KTKatarzyna Tomela
Katarzyna Tomela
AOAgnieszka Olejnik-Schmidt
Agnieszka Olejnik-Schmidt
Andrzej MackiewiczAndrzej Mackiewicz
Andrzej Mackiewicz
Marcin SchmidtMarcin Schmidt
Marcin Schmidt
Secretory IgA (SIgA) is the dominant antibody class in mucosal secretions. The majority of plasma cells producing IgA are located within mucosal membranes lining the intestines. SIgA protects against the adhesion of pathogens and their penetration into the intestinal barrier. Moreover, SIgA regulates gut microbiota composition and provides intestinal homeostasis. In this review, we present mechanisms of SIgA generation: T cell-dependent and -independent; in different non-organized and organized lymphoid structures in intestinal lamina propria (i.e., Peyer’s patches and isolated lymphoid follicles). We also summarize recent advances in understanding of SIgA functions in intestinal mucosal secretions with focus on its role in regulating gut microbiota composition and generation of tolerogenic responses toward its members.

31 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
BDBernadeta Drymel
Bernadeta Drymel
KTKatarzyna Tomela
Katarzyna Tomela
AOAgnieszka Olejnik-Schmidt
Agnieszka Olejnik-Schmidt
ŁGŁukasz Galus
Łukasz Galus
JMJacek Mackiewicz
Jacek Mackiewicz
Marcin SchmidtMarcin Schmidt
Marcin Schmidt
The gut microbiota is considered a key player modulating the efficacy of immune checkpoint inhibitor therapy. The study investigated the association between the response to anti-PD-1 therapy and the baseline gut microbiome in a Polish cohort of melanoma patients, alongside selected agents modifying the microbiome. Sixty-four melanoma patients enrolled for the anti-PD-1 therapy, and ten healthy subjects were recruited. The response to the treatment was assessed according to the response evaluation criteria in solid tumors, and patients were classified as responders or non-responders. The association between selected extrinsic factors and response was investigated using questionnaire-based analysis and the metataxonomics of the microbiota. In the responders, the Bacteroidota to Firmicutes ratio was higher, and the richness was decreased. The abundance of Prevotella copri and Bacteroides uniformis was related to the response, whereas the non-responders’ gut microbiota was enriched with Faecalibacterium prausnitzii and Desulfovibrio intestinalis and some unclassified Firmicutes. Dietary patterns, including plant, dairy, and fat consumption as well as gastrointestinal tract functioning were significantly associated with the therapeutic effects of the therapy. The specific gut microbiota along with diet were found to be associated with the response to the therapy in the population of melanoma patients.

1 March 2014 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
BFBartosz Adam Frycz
Bartosz Adam Frycz
DMDawid Murawa
Dawid Murawa
MBMaciej Borejsza-Wysocki
Maciej Borejsza-Wysocki
RMRyszard Marciniak
Ryszard Marciniak
PMPaweł Murawa
Paweł Murawa
PJPaweł Jagodziński
Paweł Jagodziński

20 August 2020 in PeerJ
Verified
Journal Article
Open access
PDF file
JKJustyna Karolak
Justyna Karolak
BGBarbara Ginter-Matuszewska
Barbara Ginter-Matuszewska
KTKatarzyna Tomela
Katarzyna Tomela
MKMichal Kabza
Michal Kabza
DNDorota M. Nowak-Malczewska
Dorota M. Nowak-Malczewska
MGMarzena Gajęcka
Marzena Gajęcka
Background: Keratoconus (KTCN) is a progressive eye disease, characterized by changes in the shape and thickness of the cornea that results in loss of visual acuity. While numerous KTCN candidate genes have been identified, the genetic etiology of the disease remains undetermined. To further investigate and verify the contribution of particular genetic factors to KTCN, we assessed 45 candidate genes previously indicated as involved in KTCN etiology based on transcriptomic and genomic data. Methods: The RealTime ready Custom Panel, covering 45 KTCN candidate genes and two reference transcripts, has been designed. Then, the expression profiles have been assessed using the RT-qPCR assay in six KTCN and six non-KTCN human corneas, obtained from individuals undergoing a penetrating keratoplasty procedure. Results: In total, 35 genes exhibiting differential expression between KTCN and non-KTCN corneas have been identified. Among these genes were ones linked to the extracellular matrix formation, including collagen synthesis or the TGF-β, Hippo, and Wnt signaling pathways. The most downregulated transcripts in KTCN corneas were CTGF, TGFB3, ZNF469, COL5A2, SMAD7, and SPARC, while TGFBI and SLC4A11 were the most upregulated ones. Hierarchical clustering of expression profiles demonstrated almost clear separation between KTCN and non-KTCN corneas. The gene expression levels determined using RT-qPCR showed a strong correlation with previous RNA sequencing (RNA-Seq) results. Conclusions: A strong correlation between RT-qPCR and earlier RNA-Seq data confirms the possible involvement of genes from collagen synthesis and the TGF-β, Hippo, and Wnt signaling pathways in KTCN etiology. Our data also revealed altered expression of several genes, such as LOX, SPARC, and ZNF469, in which single nucleotide variants have been frequently identified in KTCN. These findings further highlight the heterogeneous nature of KTCN.

5 February 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
NSNatalia Szostak
Natalia Szostak
LHLuiza Handschuh
Luiza Handschuh
ASAnna Samelak-Czajka
Anna Samelak-Czajka
KTKatarzyna Tomela
Katarzyna Tomela
BDBernadeta Drymel
Bernadeta Drymel
Anna PhilipsAnna Philips
Anna Philips
Recent research indicates that gut microbiota may be vital in the advancement of melanoma. In this study, we found that melanoma patients exhibited a distinct gut mycobiota structure compared with healthy participants. Candida albicans, Candida dubliniensis, and Neurospora crassa were more abundant in samples from patients with melanoma, whereas Saccharomyces cerevisiae and Debaryomyces hansenii were less abundant. During anti–PD-1 treatment, the relative amount of Malassezia restricta and C. albicans increased. A higher level of Saccharomyces paradoxus was associated with a positive response to anti–PD-1 treatment, whereas a higher level of Tetrapisispora blattae was associated with a lack of clinical benefits. High levels of M. restricta and C. albicans, elevated serum lactate dehydrogenase, and being overweight were linked to increased risk of melanoma progression and poorer response to anti–PD-1 treatment. Thus, this study has revealed melanoma-associated mycobiome dysbiosis, characterized by altered fungal composition and fungi species associated with a higher risk of melanoma progression, identifying a role for the gut mycobiome in melanoma progression.

2 March 2023 in Cells
Verified
Journal Article
Open access
PDF file
KTKatarzyna Tomela
Katarzyna Tomela
BDBernadeta Drymel
Bernadeta Drymel
ŁGŁukasz Galus
Łukasz Galus
JMJacek Mackiewicz
Jacek Mackiewicz
Marcin SchmidtMarcin Schmidt
Marcin Schmidt
Mariusz KaczmarekMariusz Kaczmarek
Mariusz Kaczmarek
Myeloid-derived suppressor cells (MDSC) are a subset of immature myeloid cells with suppressive activity well described in the context of cancer. They inhibit anti-tumour immunity, promote metastasis formation and can lead to immune therapy resistance. In a retrospective study, blood probes of 46 advanced melanoma patients were analysed before the first administration of anti-PD-1 immunotherapy and in the third month of treatment for MDSC, immature monocytic (ImMC), monocytic MDSC (MoMDSC) and granulocytic MDSC (GrMDSC) by multi-channel flow cytometry. Cell frequencies were correlated with response to immunotherapy, progression-free survival (PFS) and lactate dehydrogenase (LDH) serum level. Responders to anti-PD-1 therapy had higher MoMDSC levels (4.1 ± 1.2%) compared to non-responders (3.0 ± 1.2%) (p = 0.0333) before the first administration of anti-PD-1. No significant changes in MDSCs frequencies were observed in the groups of patients before and in the third month of therapy. The cut-off values of MDSCs, MoMDSCs, GrMDSCs and ImMCs for favourable 2- and 3-year PFS were established. Elevated LDH level is a negative prognostic factor of response to the treatment and is related to an elevated ratio of GrMDSCs and ImMCs level compared to patients’ LDH level below the cut-off. Our data may provide a new perspective for more careful consideration of MDSCs, and specially MoMDSCs, as a tool for monitoring the immune status of melanoma patients. Changes in MDSC levels may have a potential prognostic value, however a correlation with other parameters must be established.